Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (7,232)	$ (2,577)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	2	1
Stock-based compensation	228	672
Marketable equity securities revaluation	(644)	302
Loss from extinguishment of convertible loans		878
Accrued interest on convertible loans		36
Amortization of premium related to convertible loans		(1,188)
Loss from recognition of mandatorily redeemable Series B Preferred Stock	3,207
Change from revaluation of mandatorily redeemable Series B Preferred Stock	597
Change from revaluation of contingent obligation with respect to future revenues	1,758
Increase in license purchase obligation	150	150
Change in:
Other current assets	228	103
Accounts payable	750	75
Net cash used in operating activities	(956)	(1,548)
Cash flows from investing activities
Purchase of property and equipment	(1)
Proceeds from sale of marketable equity securities	115
Net cash provided by investing activities	114
Cash flows from financing activities
License obligation	(150)	(150)
Net proceeds from issuance of mandatorily redeemable Series B Preferred Stock	100
Loan received	247
Net cash provided by (used in) financing activities	197	(150)
Decrease in cash, cash equivalents and restricted cash	(645)	(1,698)
Cash, cash equivalents and restricted cash at the beginning of the period	759	3,183
Cash, cash equivalents and restricted cash at the end of the period	114	1,485
Supplemental disclosure of non-cash financing activities:
Common shares issued through receipt of marketable securities		765
Amount allocated to the repurchase right to existing right to future investment related to 2016 and 2017 loans - March 2019 loan amendment		(481)
Amounts that were allocated to the right for future investment - 2016 loan - March 2019 loan amendment		256
Amounts that were allocated to the right for future investment - 2017 loan - March 2019 loan amendment		386
Deemed dividends with respect to the repurchase of right for future investment - March 2019 loan amendment		104
Amount allocated to the repurchase right to existing right to future investment related to 2016 and 2017 loans - May 2019 loan extension		(152)
Amounts that were allocated to the right for future investment and warrants - 2016 loan - May 2019 loan extension		381
Amounts that were allocated to the right for future investment and warrants - 2017 loan - May 2019 loan extension		576
Deemed dividends with respect to the repurchase of right for future investment - May 2019 loan extension		81
Amount allocated to the 2016 Loan - March 2019 loan amendment		729
Amount allocated to the 2017 Loan - March 2019 loan amendment		1,037
Amount allocated to the 2016 Loan - May 2019 loan extension		634
Amount allocated to the 2017 Loan - May 2019 loan extension		922
Amounts transferred from Series B Preferred Stock investment to restricted deposit held in escrow	3,700
Investment in marketable securities (Bonus shares)	8,759
Recognition of contingent obligation with respect to future revenues	5,059
Issuance of mandatorily redeemable Series B Preferred Stock	7,400
Settlement of mandatorily redeemable series B Preferred Stock through distribution of Bonus shares	$ 6,597